Organoid drug screening
Also known as: organoid drug screen · drug screen
Library items include an automated, personalised GBM tumor-organoid drug-screening platform, and DELPHAI (preprint) which models temozolomide responses in GBM organoids. VC0097 VC0129 · preprint
Review pending Version 0.1.0 · status: draft · last expert review: not yet reviewed
Relations
| Subject | Relation | Object | Confidence | Evidence (role) |
|---|---|---|---|---|
| Organoid drug screening | associated with | Patient-derived GBM organoids | high | VC0097 supports |
Appears in research topics
Appears in library items (2)
Items whose title, tags or one-line summary match this entity (derived from the data), plus the items cited as evidence for the description.
- VC0097 Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. — Jungwirth G et al., NPJ precision oncology, 2026
- VC0129 · preprint DELPHAI, AI Agent for Predicting Drug Response and Resistance — Peng et al., preprint, 2025
For research and education only. Not medical advice and not a recommendation of any diagnosis, treatment or product. Patients should consult their own physicians.